The Recessive X Chromosome Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Recessive X Chromosome Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Recessive X Chromosome Disorders. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Recessive X Chromosome Disorders and features dormant and discontinued products.

GlobalData tracks 201 drugs in development for Recessive X Chromosome Disorders by 142 companies/universities/institutes. The top development phase for Recessive X Chromosome Disorders is preclinical with 110 drugs in that stage. The Recessive X Chromosome Disorders pipeline has 177 drugs in development by companies and 24 by universities/ institutes. Some of the companies in the Recessive X Chromosome Disorders pipeline products market are: Sarepta Therapeutics, Dyne Therapeutics and Pepgen.

The key targets in the Recessive X Chromosome Disorders pipeline products market include Dystrophin (DMD), Utrophin (Dystrophin Related Protein 1 or DRP1 or UTRN), and Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1).

The key mechanisms of action in the Recessive X Chromosome Disorders pipeline product include Dystrophin (DMD) Activator with 79 drugs in Pre-Registration. The Recessive X Chromosome Disorders pipeline products include 13 routes of administration with the top ROA being Intravenous and 13 key molecule types in the Recessive X Chromosome Disorders pipeline products market including Small Molecule, and Antisense Oligonucleotide.

Recessive X Chromosome Disorders overview

A recessive X chromosome disorder, also known as an X-linked recessive disorder, is a genetic condition caused by a mutation on one of the X chromosomes, one of the two sex chromosomes. Typically, males have one X and one Y chromosome (XY), while females have two X chromosomes (XX). In recessive X-linked disorders, the mutated gene is located on the X chromosome and typically affects males more severely, as they have only one X chromosome. Common examples include hemophilia, Duchenne muscular dystrophy, and red-green color blindness. Carrier females, with one affected X chromosome and one normal X chromosome, often do not show symptoms but can pass the disorder to their offspring.

For a complete picture of Recessive X Chromosome Disorders’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.